source
- Angelini to acquire Catalyst Pharmaceuticals for $4.1 billion, adding rare CNS drug portfolioAngelini Pharma announced it will purchase Catalyst Pharmaceuticals in a cash transaction valued at about $4.1 billion. The agreement pays $31.50 per Catalyst share, representing a 21% premium to…
- Sarepta's Elevidys sales beat forecasts but dip again, prompting stock slide and shift to RNA pipelineSarepta Therapeutics reported that its gene therapy Elevidys generated net product revenue that exceeded Wall Street estimates for the first quarter. However, sales continued to decline compared wi…